Kraig Biocraft Laboratories Announces the Successful Creation of New Commercial Hybrid Transgenic Silkworms

Independent Testing Confirms That the New Hybrids Are Producing Recombinant Silk Which Significantly Exceeds Traditional Silk in Both Elasticity and Tensile Strength

LANSING, MI, May 31, 2011 (MARKETWIRE via COMTEX) — Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced that it successfully mated its transgenic silkworms, which produce recombinant spider silk, with a physically larger commercial strain of the domesticated silkworm. The resulting hybrid silkworms are larger than Kraig’s original transgenic silkworms and are also producing significantly larger recombinant silk cocoons.

Independent laboratory testing confirmed that the transgenic/commercial silkworm hybrids are producing silk which is significantly stronger and more flexible than that of the original commercial strain. The new recombinant spider silk is a composite silk composed of both native silkworm silk proteins and spider silk proteins (as in the original Kraig transgenic silkworm whose development was announced in late September).

Kim Thompson, the Company’s CEO and Founder, stated, “The new hybrid was specifically designed for commercialization and has been designated ‘Monster Hybrid,’ which is the successful cross between our transgenic silkworms and a much larger commercial strain.

“The result is a large, robust, commercial sized silkworm which spins a larger commercial sized cocoon composed of recombinant spider silk like the original transgenic. The new hybrid was specifically designed to generate greater recombinant silk production capacity than our original first generation transgenic.”

“This larger hybrid transgenic will be the platform for our commercialization ramp up,” Thompson continued. “Now that the strength and elasticity qualities have been confirmed, we can move forward with cultivating the hybrids in commercially viable quantities. We are working diligently to increase our stock of the new strain in order to increase our production capacity.”


About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information please visit .


Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495

This entry was posted on by .